Treatment of latent tuberculosis infection in HIV: shorter or longer?

Current HIV/AIDS Reports
Anna K Person, Timothy R Sterling

Abstract

Nine months of daily isoniazid is efficacious in treating latent M. tuberculosis infection, but completion rates are low, limiting treatment effectiveness. In 2011, three important studies were published involving novel regimens for the treatment of latent M. tuberculosis infection. At least 36 months of isoniazid was more effective than 6 months of isoniazid in one study, but not in another-both of which were conducted among tuberculin skin test positive HIV-infected adults living in high tuberculosis incidence settings. Three months of once-weekly isoniazid plus rifapentine or twice-weekly isoniazid plus rifampin (both given under direct observation) resulted in tuberculosis rates similar to those seen with 6 months of isoniazid among HIV-infected persons in high tuberculosis incidence settings. Three months of once-weekly, directly-observed isoniazid plus rifapentine was at least as effective as 9 months of daily isoniazid among predominantly HIV-uninfected persons living in low and medium tuberculosis incidence countries. The 3-month once-weekly isoniazid plus rifapentine regimen demonstrates promise for treatment of latent M. tuberculosis infection in HIV-infected persons.

References

Oct 31, 2001·AIDS·J L JohnsonUNKNOWN Uganda-Case Western Reserve University Research Collaboration
Jan 18, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Guilherme Santoro-LopesMauro Schechter
Feb 14, 2004·American Journal of Respiratory and Critical Care Medicine·Marc WeinerUNKNOWN Tuberculosis Trials Consortium
Jun 3, 2004·American Journal of Respiratory and Critical Care Medicine·Dick MenziesKevin Schwartzman
Apr 22, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lillian MteiC Fordham von Reyn
May 18, 2006·Emerging Infectious Diseases·Maria Elvira BalcellsAlison D Grant
Mar 21, 2009·American Journal of Respiratory and Critical Care Medicine·David P HollandJason E Stout
Oct 2, 2009·Chest·C Robert HorsburghUNKNOWN Tuberculosis Epidemiologic Studies Consortium
Nov 17, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Panayiotis D Ziakas, Eleftherios Mylonakis
Jan 22, 2010·The Cochrane Database of Systematic Reviews·Christopher AkoloJimmy Volmink
Apr 16, 2011·Lancet·Lori Elizabeth Dodd, Robert John Wilkinson
Jul 8, 2011·The New England Journal of Medicine·Neil A MartinsonRichard E Chaisson
Jul 8, 2011·The New England Journal of Medicine·Shabir A MadhiUNKNOWN P1041 Study Team
Jul 16, 2011·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·S D LawnR Wood
Dec 14, 2011·The New England Journal of Medicine·Timothy R SterlingUNKNOWN TB Trials Consortium PREVENT TB Study Team

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Related Papers

Therapeutic Advances in Respiratory Disease
Madhavi J Parekh, Neil W Schluger
The Indian Journal of Medical Research
Dick MenziesBadriah Al Otaibi
American Journal of Respiratory and Critical Care Medicine
Ian M RosenthalEric L Nuermberger
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
D ShepardsonW R Mac Kenzie
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
D L Cohn
© 2021 Meta ULC. All rights reserved